港股异动 | 乐普生物-B(02157)午后涨超6% MRG006A治疗晚期肝癌I期临床数据优异

智通财经06-12

智通财经APP获悉，乐普生物-B(02157)午后涨超6%，截至发稿，涨4.74%，报3.98港元，成交额4149.5万港元。消息面上，乐普生物在2026 ASCO上披露的MRG006A针对标准治疗失败后的晚期肝癌患者的I期临床试验数据相当优异。MRG006A切入的是全球尚无获批ADC的肝癌领域，代表的是尚未被充分开发的新路径，又已经初步跨过临床验证门槛。意味着它有可能成为下一款具备BD想象空间的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2642257725?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-12 14:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642257725","market":"us","top_or_hot":-1,"title":"港股异动 | 乐普生物-B(02157)午后涨超6% MRG006A治疗晚期肝癌I期临床数据优异","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，乐普生物-B(02157)午后涨超6%，截至发稿，涨4.74%，报3.98港元，成交额4149.5万港元。消息面上，乐普生物在2026 ASCO上披露的MRG006A针对标准治疗失败后的晚期肝癌患者的I期临床试验数据相当优异。MRG006A切入的是全球尚无获批ADC的肝癌领域，代表的是尚未被充分开发的新路径，又已经初步跨过临床验证门槛。意味着它有可能成为下一款具备BD想象空间的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1453620.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 乐普生物-B(02157)午后涨超6% MRG006A治疗晚期肝癌I期临床数据优异</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 乐普生物-B(02157)午后涨超6% MRG006A治疗晚期肝癌I期临床数据优异\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-12 14:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1453620.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，乐普生物-B(02157)午后涨超6%，截至发稿，涨4.74%，报3.98港元，成交额4149.5万港元。消息面上，乐普生物在2026 ASCO上披露的MRG006A针对标准治疗失败后的晚期肝癌患者的I期临床试验数据相当优异。MRG006A切入的是全球尚无获批ADC的肝癌领域，代表的是尚未被充分开发的新路径，又已经初步跨过临床验证门槛。意味着它有可能成为下一款具备BD想象空间的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1453620.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1453620.html","article_id":"2642257725","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642257725","pubTimestamp":1781247321,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，乐普生物-B午后涨超6%，截至发稿，涨4.74%，报3.98港元，成交额4149.5万港元。消息面上，乐普生物在2026 ASCO上披露的MRG006A针对标准治疗失败后的晚期肝癌患者的I期临床试验数据相当优异。MRG006A切入的是全球尚无获批ADC的肝癌领域，代表的是尚未被充分开发的新路径，又已经初步跨过临床验证门槛。值得注意的是，乐普生物此前宣布其自主研发的靶向 CDH17 的抗体偶联药物MRG007 的新药临床试验申请正式获得国家药品监督管理局药品审评中心受理。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","02157":"乐普生物","BK4585":"ETF&股票定投概念","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard"},"translate_title":"Hong Kong stock changes | Lepu Bio-B (02157) rose by more than 6% in the afternoon MRG006A treatment of advanced liver cancer Phase I clinical data excellent","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1.5,"02157":1.5},"content_text":"智通财经APP获悉，乐普生物-B(02157)午后涨超6%，截至发稿，涨4.74%，报3.98港元，成交额4149.5万港元。消息面上，乐普生物在2026 ASCO上披露的MRG006A针对标准治疗失败后的晚期肝癌患者的I期临床试验数据相当优异。MRG006A切入的是全球尚无获批ADC的肝癌领域，代表的是尚未被充分开发的新路径，又已经初步跨过临床验证门槛。意味着它有可能成为下一款具备BD想象空间的中国first-in-class ADC项目。值得注意的是，乐普生物此前宣布其自主研发的靶向 CDH17 的抗体偶联药物MRG007 的新药临床试验申请正式获得国家药品监督管理局药品审评中心受理。本次新临床受理标志着其在消化道肿瘤领域的临床开发迈入关键节点，未来有望为国内数百万晚期消化道肿瘤患者带来全新治疗选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642257725","isCrawlerRequest":true}